S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data (2014/4/8)|
|Pharmacyclics Announces Date of Conference call to discuss Financial Results for Fourth Quarter and Year End 2013 (2014/2/14)|
|BioClinica Technology Supports Pharmacyclics in Achieving Early Approval of IMBRUVICA™ and Breakthrough Therapy Designations for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) (2014/3/11)|
|Pharmacyclics Reports Second Quarter 2013 Results ()|
|Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013 (2013/11/1)|
|Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results (2014/2/20)|
|Pharmacyclics Reports Third Quarter 2013 Results ()|
|U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy (2013/11/13)|
|U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy (2014/2/12)|
|Independent Data Monitoring Committee recommends Phase III study of IMBRUVICA™ (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival ()|
Click above to view more mutual fund data and stats for pcyc - Pharmacyclics, Inc..